Anthony Doyle has been named chief financial officer of BioCryst Pharmaceuticals (NASDAQ: [[ticker:BCRX]]). He is joining the Durham, NC, rare disease drug developer from Worldwide Clinical Trials, where he has been CFO since 2014. His experience also includes several roles at General Electric (NYSE: [[ticker:GE]]). BioCryst is awaiting an FDA decision for berotralstat, a treatment for hereditary angioedema.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
